A long term disease named  Ankylosing   Spondylitis has been linked to a higher risk of cardiovascular problems. A number of factors could be responsible for this increased risk, including the drugs used to treat this painful condition.

No two patients with ankylosing spondylitis are exactly the same. As such, a drug treatment that works for one patient may not work for the other. When one drug isn't working out, patients may turn to another drug.

Many experts recommend that rheumatoid arthritis patients get early drug treatment to slow down their disease and prevent disability. With so many drug options, it's important to know the safety of each drug.

A few years ago, the FDA warned that certain drugs may raise the risk of cancer in children with juvenile arthritis. While it still seems these children are more prone to cancer, the drugs might not be to blame.

A class of drugs is now under suspicion of causing cancer in children, adolescents and young adults under the age of 30. These are called Tumor Necrosis Factor (TNF) blockers, and the U.S. Food and Drug Administration (FDA) recently released an update regarding its ongoing safety review of these drugs.

Rheumatoid Arthritis (RA) increases a person's risk for some types of cancer such as lymphoma and lowers the risk of other types such as colon and breast. Now, it seems medications for RA increase the risk for another kind of cancer.

Early reports indicating drugs treating psoriasis were linked to major cardiovascular events seem to lack evidence.

Australian researchers have discovered a genetic link between a certain type of spinal arthritis and inflammatory bowel disease.